[Clinical study of ganshao capsule in treating clomiphene-resistant polycystic ovarian syndrome].
OBJECTIVE
To assess the efficacy and safety of Ganshao Capsule (GSC) in treating clomiphene (CC)-resistant hyperandrogenemic polycystic ovarian syndrome (PCOS), and to explore the feasibility of using CC for improving ovulation induction after withdrawal of GSC.


METHODS
Twenty-seven PCOS patients were given GSC for 8 weeks (2 cycles). Changes in serum reproductive hormone, body mass index (BMI), adverse reaction, as well as pelvic ultrasonographic feature were observed before treatment, at the end of 4 weeks and 8 weeks after treatment. After stopping GSC medication, CC was used to induce ovulation in patients whose serum testosterone (T) < (2.1+/-0.8) nmol/L but without ovulation. Condition of follicle growth and effect of GSC were monitored.


RESULTS
After 4 weeks of treatment, serum reproductive hormones were significantly changed. At the end of 8 weeks, bilateral ovarian volume, number of follicles, and diameter of follicles were significantly reduced, and endometrium obviously thinned. Within 2 months after stopping medication, 6 in the 27 patients got natural ovulation, and 2 natural pregnancy. In the other 19 patients who received ovulation induction during the 37th cycles, 17 had ovulation in the 25th cycles, 7 got pregnancy, the ovulation rate being 89.5%, ovulation cycle rate 67.6%, pregnant rate 36.8%, and pregnant cycle rate 28.0%.


CONCLUSIONS
Endometrium, ovarian morphology and BMI got significant improvement in PCOS patients with CC- resistance and hyperandrogenemia. The sensitivity to ovulation induction with CC were also improved.
Yang
Yan-Sheng
YS
First Hospital, Shanxi Medical University, Taiyuan. yxdwzh168@163.com
Zhang
Yong-Luo
YL
D000328:Adult; D002214:Capsules; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D008517:Phytotherapy; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood
D002214:Capsules; D004365:Drugs, Chinese Herbal; D005300:Fertility Agents, Female; D002996:Clomiphene; D011388:Prolactin; D007986:Luteinizing Hormone